This Amendment No. 1 (Amendment No. 1) to Schedule 13D relates to
the common stock, par value $0.0001 per share (Common Stock), of Science 37 Holdings, Inc. (formerly known as LifeSci Acquisition II Corp.), a Delaware corporation (the Issuer), and amends and supplements
the initial statement on Schedule 13D filed by the Reporting Persons on October 18, 2021 (the Original Schedule 13D and, as amended and supplemented by this Amendment No. 1, the Schedule 13D). This
Amendment No. 1 is only being filed to correct the number and percentage of shares of Common Stock beneficially owned by the Reporting Persons following the Business Combination as reported in the Original Schedule 13D. There have been no
transactions in the Common Stock by the Reporting Persons since the filing of the Original Schedule 13D, and information reported in the Original Schedule 13D remains in effect except to the extent that it is amended or superseded by information
contained in this Amendment No. 1. Capitalized terms used but not defined in this Amendment No. 1 shall have the same meanings ascribed to them in the Original Schedule 13D.
Item 3. Source and Amount of Funds or Other Consideration
Item 3 of the Original Schedule 13D is hereby amended and restated as follows:
On October 6, 2021 (the Closing Date), in connection with the closing of the transactions contemplated by the Agreement and Plan of
Merger, dated as of May 6, 2021 (the Merger Agreement), by and among LifeSci Acquisition II Corp. (LSAQ), LifeSci Acquisition II Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of LSAQ
(Merger Sub) and Science 37, Inc., a Delaware corporation (Science 37), among other things, Merger Sub merged with and into Science 37 (the Business Combination) with Science 37 surviving the
merger as a wholly-owned subsidiary of LSAQ. Following the Business Combination, LSAQ was renamed Science 37 Holdings, Inc. In exchange for their ownership of preferred stock of Science 37 prior to the Business Combination, Pharma LLC
received 16,879,797 shares of Common Stock of the Issuer in accordance with the terms of the Merger Agreement.
Immediately prior to the closing of the
Business Combination, Pharma LLC also purchased 500,000 shares of Common Stock in a private placement at a purchase price of $10.00 per share (the PIPE Investment). Pharma LLCs payment of the purchase price in the PIPE
Investment was funded through the working capital of Pharma LLC.
Item 5. Interest in Securities of the Issuer
Item 5(a)-(c) of the Original Schedule 13D is hereby amended and restated as follows:
The information contained in rows 7, 8, 9, 10, 11 and 13 on each of the cover pages of this Schedule 13D and the information set forth or incorporated in Items
3 and 4 is incorporated by reference in its entirety into this Item 5.
(a), (b) The following disclosure assumes that there are 114,707,150 shares of
Common Stock outstanding, as set forth in the Issuers Current Report on Form 8-K filed with the Securities and Exchange Commission (the SEC) on October 13, 2021.
Pursuant to Rule 13d-3 of the rules and regulations promulgated by the SEC pursuant to the Securities Exchange Act of
1934, as amended (the Exchange Act), the Reporting Persons may be deemed to beneficially own an aggregate of 17,379,797 shares of Common Stock, representing approximately 15.2% of shares of Common Stock outstanding.
Any beneficial ownership of Common Stock by any of the persons listed on Schedule I is set forth on Schedule I of the Original Schedule 13D.
(c) Except as set forth in Item 3 of this Schedule 13D, none of the Reporting Persons, nor to its knowledge, any person listed on Schedule I of the Original
Schedule 13D, has effected any transactions in Common Stock during the past 60 days.